Council for Innovation Promotion

New Op-Ed from C4IP Co-Chair Andrei Iancu: To succeed, modern tech needs updated patent law

C4IP Co-Chair and former USPTO Director Andrei Iancu recently published an opinion piece in The Hill that discusses the current confusion around patent eligibility and explains how the Patent Eligibility Restoration Act (PERA) will “set matters right.” Should modern inventions like genetic blood tests to detect disease biomarkers or artificial intelligence be patent-eligible? According to

New Op-Ed from C4IP Co-Chair Andrei Iancu: To succeed, modern tech needs updated patent law Read More »

New Op-Ed from Former U.S. Commerce Secretary Gary Locke: Innovation drives Minnesota’s economy. Congress should lend a hand.

Former U.S. Ambassador to China, U.S. Secretary of Commerce, and Governor of Washington Gary Locke recently authored an opinion piece in the Minnesota Star Tribune highlighting the importance of two bipartisan bills to Minnesota’s innovation ecosystem. According to Locke, the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act and the Patent Eligibility Restoration

New Op-Ed from Former U.S. Commerce Secretary Gary Locke: Innovation drives Minnesota’s economy. Congress should lend a hand. Read More »

Inventor Spotlight: William Shockley, John Bardeen, and Walter Brattain

C4IP is recognizing William Shockley, John Bardeen, and Walter Brattain, whose invention of the transistor made modern electronics possible. Shockley, Bardeen, and Brattain met in the 1940s at Bell Laboratories when they were hand-picked to work on developing a transistor, a device for generating and amplifying electrical signals. The trio succeeded after just two years,

Inventor Spotlight: William Shockley, John Bardeen, and Walter Brattain Read More »

Fact Check: Debunking Myths About Patents in the Pharmaceutical Industry

Activists affiliated with the Initiative for Medicines, Access & Knowledge (I-MAK) and R Street Institute have propagated false narratives about how patents stifle competition in the drug industry and keep generic drugs from coming to market. These erroneous arguments include the ideas that drug developers ‘game’ the FDA’s Orange Book, that they file unnecessary patents

Fact Check: Debunking Myths About Patents in the Pharmaceutical Industry Read More »

C4IP Coalition Updates: October 2024

October was a productive month for C4IP! Here’s a roundup of all that we accomplished over the past month. October Highlights: Spotlighting New Insights on Patent Quality On September 30, the nonprofit, nonpartisan Sunwater Institute released a policy report, “Patent Quality in the United States: Findings and Suggestions for Policymakers.” The report reviewed the U.S.

C4IP Coalition Updates: October 2024 Read More »

New Op-Ed from C4IP Co-Chair Andrei Iancu: Bill Is Key To Protecting US Economy From Patent Piracy

C4IP Co-Chair and former USPTO Director Andrei Iancu recently published an opinion piece in Law360 highlighting the importance of passing the bipartisan RESTORE Patent Rights Act. This bill, introduced by Senators Chris Coons (D-DE) and Tom Cotton (R-AR) and Representatives Nathaniel Moran (R-TX) and Madeleine Dean (D-PA), would reinstate injunctions as the default remedy in

New Op-Ed from C4IP Co-Chair Andrei Iancu: Bill Is Key To Protecting US Economy From Patent Piracy Read More »

Fact Check: The RESTORE Patent Rights Act Would Bolster America’s Innovation Economy

The RESTORE Patent Rights Act, introduced in July by a bipartisan group of senators and representatives, would be a pivotal legislative milestone for promoting innovation, if enacted into law. This bill would reestablish injunctive relief as the default legal remedy for patent infringement, preventing patent infringers from using others’ IP and ultimately facing little more

Fact Check: The RESTORE Patent Rights Act Would Bolster America’s Innovation Economy Read More »

Scroll to Top